PharmaSGP Holding Third Quarter 2024 Earnings: In Line With Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 30 2024
0mins
Should l Buy ?
Source: Yahoo Finance
Financial Performance: The company reported a revenue of €30.3 million (up 17%) and a net income of €5.37 million (up 12%) for the third quarter of 2023, with an EPS increase from €0.40 to €0.45.
Future Outlook: Revenue is expected to grow at an average rate of 7.3% per annum over the next three years, outperforming the German Pharmaceuticals industry's forecasted growth of 3.4%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
